Weil served as antitrust counsel to Allergan, a global pharmaceutical leader, in AbbVie’s proposed acquisition of Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion. The transaction closed on May 07, 2020.

Weil’s antitrust team included global Head of Antitrust/Competition Steven Newborn, partners Ann Malester and Brianne Kucerik, counsel Vadim Brusser, and associates Natalie Hayes, Jonathan Goldsmith and Vivian Wang.